Stocktoria
MIMEDX GROUP, INC. MDXG
MIMEDX GROUP, INC. (MDXG) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $418.6M at a 11.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.622 |
| Retained earnings / assets | -0.125 |
| EBIT / assets | 0.186 |
| Equity / liabilities | 2.979 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| MDXG | MIMEDX GROUP, INC. | 5/9 | 8.06 | 12 | +20% |
| AORT | ARTIVION, INC. | 7/9 | 3.05 | 117.3 | +13.6% |
| ARAY | ACCURAY INC | 6/9 | -1.53 | — | +2.7% |
| GKOS | GLAUKOS Corp | 2/9 | 0.74 | — | +32.3% |
| TCMD | TACTILE SYSTEMS TECHNOLOGY INC | 7/9 | 8.52 | 35.8 | +12.5% |
| ANGO | ANGIODYNAMICS INC | 5/9 | -1.82 | — | +9.5% |
| PRCT | PROCEPT BioRobotics Corp | 3/9 | 2.18 | — | +37.2% |
About MIMEDX GROUP, INC.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery, and various orthopedic repairs and reconstructions. The company's products are used in the areas of wound care, burn, and surgical fields in healthcare. It sells its products through direct sales force and independent sales agents, as well as to individual customers and independent distributors in the United States. The company has a strategic alliance with Vaporox, Inc. for the promotion of their wound care offerings. The company was founded in 2006 and is headquartered in Marietta, Georgia.
FAQ
Is MDXG financially healthy?
MIMEDX GROUP, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does MDXG pay a dividend?
No, MIMEDX GROUP, INC. does not currently pay a dividend.
How profitable is MDXG?
In FY2025, MIMEDX GROUP, INC. had a net margin of 11.6% and a return on equity of 18.9%.
Is MDXG overvalued or undervalued?
MIMEDX GROUP, INC. trades at about 13.4× trailing earnings — below its 10-year norm (10-year range 16.0×–163.0×, median 31.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for MDXG?
The average Wall-Street price target for MIMEDX GROUP, INC. is $6.60, about 54.2% above the recent price, from 5 analysts (consensus: strong buy).
Is MDXG a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on MIMEDX GROUP, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 12.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.